|
| Press Releases |
|
 |
|
| Wednesday, September 5, 2018 |
|
|
NANOBIOTIX half year results for the six months ended June 30, 2018 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended June 30 2018, from the consolidated financial statements at June 30, 2018 that have been reviewed by the supervisory board dated September 4, 2018. more info >> |
|
| Friday, July 27, 2018 |
|
|
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities. more info >> |
|
| Friday, June 22, 2018 |
|
|
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS). more info >> |
|
| Wednesday, June 6, 2018 |
|
|
NANOBIOTIX' Management Statement on Recent Share Price Variation |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, communicates today regarding the recent evolution of its share price. more info >> |
|
| Friday, May 4, 2018 |
|
|
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism of action. more info >> |
|
| Wednesday, April 18, 2018 |
|
|
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that preclinical data evaluating the activation of the cGAS-STING pathway by NBTXR3 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois (April 14-18, 2018). more info >> |
|
| Wednesday, April 11, 2018 |
|
|
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston TX, to work on NBTXR3, Nanobiotix's lead product. more info >> |
|
| Friday, March 30, 2018 |
|
|
Nanobiotix 2017 Annual Results |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017. more info >> |
|
| Monday, January 22, 2018 |
|
|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of intermediate data on the safety and feasibility in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors. more info >> |
|
| Thursday, January 11, 2018 |
|
|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
華營控股捐贈港幣一百萬元 支援大埔火災災民
Dec 22, 2025 18:17 HKT/SGT
|
|
|
Sri Lanka and the Middle East's top real estate achievements recognised at 2025 PropertyGuru Asia Property Awards
Dec 22, 2025 16:57: JST
|
|
|
MiniMax通過港交所聆訊 衝刺「AGI全球第一股」
Dec 22, 2025 15:59 HKT/SGT
|
|
|
MiniMax通过港交所聆讯 冲刺「AGI全球第一股」
Dec 22, 2025 15:46 HKT/SGT
|
|
|
三菱重工グループ、デジタル人材育成を加速
Dec 22, 2025 12:00: JST
|
|
|
聯想之星收穫第10個IPO
Dec 22, 2025 11:41 HKT/SGT
|
|
|
国内初、三菱重工とエクシオグループが二相式DLC方式のGPUサーバー構築・商用利用開始
Dec 22, 2025 11:40: JST
|
|
|
联想之星收获第10个IPO
Dec 22, 2025 11:30 HKT/SGT
|
|
|
印象大紅袍宣佈全球發售定價 每股發售股份發售價3.6港元 集資港幣1.3億元
Dec 22, 2025 10:00 HKT/SGT
|
|
|
印象大红袍宣布全球发售定价 每股发售股份发售价3.6港元 集资港币1.3亿元
Dec 22, 2025 10:00 HKT/SGT
|
|
|
Sri Lanka and the Middle East's top real estate achievements recognised at 2025 PropertyGuru Asia Property Awards
Dec 22, 2025 09:00 HKT/SGT
|
|
|
西藏智汇矿业登陆港股：从高原走向国际 独特资源禀赋释放长期增长潜力
Dec 19, 2025 16:15 HKT/SGT
|
|
|
西藏智匯礦業登陸港股：從高原走向國際 獨特資源稟賦釋放長期增長潛力
Dec 19, 2025 15:35 HKT/SGT
|
|
|
A New Benchmark for Specialized Technology Stocks in Hong Kong! CiDi's Listing Marks a New Chapter in Commercial Intelligent Driving
Dec 19, 2025 10:30 HKT/SGT
|
|
|
トヨタ、米国生産トヨタ車の26年からの日本導入を検討
Dec 19, 2025 10:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
